PROJECT -Continue

Differentiation of malignant pleural mesothelioma from benign asbestos-related
pleural disease with microRNA and gene expression profiling

Centers:

. ESOGU - APKAM, Eskisehir, Turkey

. Mayo Clinic, department of Chest Diseases, Rochester, USA

Information:

Dr. Guntulu Ak: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Dr. S Tomaszek

 

PROJECT - Continue

Mesothelin and midkine analysis in serum samples of mesothelioma cases.

Centers:

. ESOGU - APKAM, Eskisehir, Turkey

. Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute
666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan

Information:

Dr. Güntülü Ak: This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Masatoshi Tagawa: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

PROJECT - Completed

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

Centers:

. ESOGU-APKAM, Eskisehir, Turkey

. Karolinska Institute Departmentf of Pathology, Stockholm, Sweden

Information:

Dr. Filip Mundt: This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Sertaç Arslan: This email address is being protected from spambots. You need JavaScript enabled to view it.

(Araştırma makalesi olarak yayınlandı)

 

PROJECT - Continue

Comparison of N-ERC/Mesothelin, C-ERC/Mesothelin, Osteopontin, Syndecan-1 and Hyaluronan as serum markers of patients for the diagnosis of malignant pleural diseases.

Centers:

. ESOGU - APKAM, Eskisehir, Turkey

. Karolinska Institute Departmentf of Pathology, Stockholm, Sweden

Information:

Dr.Muzaffer Metintaş: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

PROJECT - Completed

Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.

Centers:

. ESOGU - APKAM, Eskisehir, Turkey

. Karolinska Institute Department of Pathology, Stockholm, Sweden

Information:

Dr. Muzaffer Metintas: This email address is being protected from spambots. You need JavaScript enabled to view it.

(Araştırma makalesi olarak yayınlandı)

 

PROJECT - Completed

Prognostic and diagnostic value of Syndecan-1 in diagnosis of malignant mesothelioma

Centers:

. Karolinska Institute Department of Pathology, Stockholm, Sweden

. ESOGU - APKAM, Eskişehir, Turkey

Information:

This email address is being protected from spambots. You need JavaScript enabled to view it.

(Araştırma makalesi olarak yayınlandı)